PTC Therapeutics completes acquisition of Sangamo’s ST-920 Fabry gene therapy asset

• PTC Therapeutics completed its acquisition of Sangamo’s ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease.
• A rolling BLA filing to the FDA for accelerated approval is expected to be completed in Q4 2026.
• ST-920, also known as isaralgagene civaparvovec, targets long-term α-Gal A enzyme production to reduce Gb3 levels and cut reliance on ERT.
• The program holds FDA Orphan Drug, Fast Track, and RMAT designations, with similar designations in Europe and the UK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609211630PR_NEWS_USPR_____NY53128) on September 21, 2026, and is solely responsible for the information contained therein.